dMed Biopharmaceutical, a clinical contract research organisation (CRO) with operations in China and the US, announced on Thursday that it has raised $100 million in a Series C round of financing led by Fidelity Management & Research Company.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $52.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at firstname.lastname@example.org